AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUROSCIENTIFIC BIOPHARMACEU

0.105

-0.005-4.55%

Volume:210.97K

Turnover:22.89K

Market Cap:34.92M

PE:-8.33

High:0.110

Open:0.110

Low:0.105

Close:0.110

52wk High:0.260

52wk Low:0.033

Shares:332.58M

Float Shares:243.14M

Volume Ratio:1.19

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.013

EPS(LYR):-0.013

ROE:-16.65%

ROA:-11.21%

PB:2.08

PE(LYR):-8.34

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

NeuroScientific Biopharmaceuticals Ltd-Investor Webinar Update

THOMSON REUTERS

NeuroScientific Biopharmaceuticals Ltd-Clinical & Scientific Advisory Board Appointed

THOMSON REUTERS

NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator

MT Newswires Live

NeuroScientific Says Review of Biotechnology Firm's Data Shows 'Promising' Results for StemSmart Therapy in Renal Transplants, Shares Fall 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NSB.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NSB.AU\",,,,,undefined,":{"symbol":"NSB.AU","market":"AU","secType":"STK","nameCN":"NEUROSCIENTIFIC BIOPHARMACEU","latestPrice":0.105,"timestamp":1765516320000,"preClose":0.11,"halted":0,"volume":210967,"delay":0,"nameEN":"NEUROSCIENTIFIC BIOPHARMACEU","floatShares":243142540,"shares":332575706,"eps":-0.0126,"marketStatus":"Market Closed","change":-0.005,"latestTime":"12-12 16:12:00 AEDT","open":0.11,"high":0.11,"low":0.105,"amount":22888,"amplitude":0.045455,"askPrice":0.11,"askSize":31018,"bidPrice":0.105,"bidSize":502142,"shortable":3,"etf":0,"ttmEps":-0.0126,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1765753200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.11,"openAndCloseTimeList":[[1765494000000,1765515600000]],"volumeRatio":1.1851532687528568,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NSB.AU\",,,,,undefined,":{"symbol":"NSB.AU","floatShares":243142540,"roa":"-11.21%","roe":"-16.65%","lyrEps":-0.012583,"volumeRatio":1.1851532687528568,"shares":332575706,"dividePrice":0,"high":0.11,"amplitude":0.045455,"preClose":0.11,"low":0.105,"week52Low":0.033,"pbRate":"2.08","psRate":"210.27","week52High":0.26,"institutionHeld":0,"latestPrice":0.105,"committee":0.883645,"eps":-0.0126,"divideRate":0,"volume":210967,"delay":0,"ttmEps":-0.0126,"open":0.11,"prevYearClose":0.033,"prevWeekClose":0.115,"prevMonthClose":0.12,"prevQuarterClose":0.165,"fiveDayClose":0.115,"twentyDayClose":0.135,"sixtyDayClose":0.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSB.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582313277","title":"NeuroScientific Biopharmaceuticals Ltd-Investor Webinar Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582313277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582313277?lang=en_us&edition=fundamental","pubTime":"2025-11-12 07:00","pubTimestamp":1762902046,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nTUEP52KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2581831850","title":"NeuroScientific Biopharmaceuticals Ltd-Clinical & Scientific Advisory Board Appointed","url":"https://stock-news.laohu8.com/highlight/detail?id=2581831850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581831850?lang=en_us&edition=fundamental","pubTime":"2025-11-06 06:28","pubTimestamp":1762381700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUE5PS0DC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSB.AU","BK7067"],"gpt_icon":0},{"id":"2573392439","title":"NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2573392439","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573392439?lang=en_us&edition=fundamental","pubTime":"2025-10-07 12:44","pubTimestamp":1759812275,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals  said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell  technology, according to a Tuesday Australian bourse filing.Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NSB.AU","BK4150","MSC","XAO.AU","BK7067","XJO.AU","XKO.AU","BK4575"],"gpt_icon":0},{"id":"2562799788","title":"NeuroScientific Says Review of Biotechnology Firm's Data Shows 'Promising' Results for StemSmart Therapy in Renal Transplants, Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562799788","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562799788?lang=en_us&edition=fundamental","pubTime":"2025-08-27 13:16","pubTimestamp":1756271798,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals  said that a review of historical studies, data, findings, and publications following the acquisition of Isopogen WA found that StemSmart mesenchymal stromal cell  therapy showed \"promising\" results in two early studies in renal transplantation, according to a Wednesday Australian bourse filing.Isopogen WA is the holder of StemSmart, a patented stem cell technology.The studies support further clinical development and the potential of StemSmart MSC in both preventing and treating graft failure and rejection, the firm noted.A case series of 10 adult patients with treatment-refractory acute renal rejection following kidney transplants were treated with StemSmart MSC as a salvage and adjunctive therapy. Eight out of 10 patients retained their kidney following the infusion.A second study undertaken in 12 adults undergoing deceased-donor renal transplantation showed that StemSmart MSC infusion was well tolerated and safe, and the results were \"encouraging\" ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4150","BK7067","NSB.AU","BK4575","MSC"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NSB.AU\",params:#limit:6,delay:true,,,undefined,":[]}}